VIVUS to Highlight Integrated Approach to More Effective Weight Management in Panel Discussion at the Cleveland Clinic 2019 Medical Innovation Summit
October 21, 2019 07:30 ET
|
VIVUS, Inc.
CAMPBELL, Calif., Oct. 21, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, announced today that John Amos, Chief Executive Officer, will participate...
VIVUS Announces Acceptance of Qsymia Decentralized Marketing Authorization Application in Europe
October 07, 2019 07:30 ET
|
VIVUS, Inc.
CAMPBELL, Calif., Oct. 07, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, announced today that European regulatory agencies in Sweden, Denmark,...
VIVUS Initiates Pay Down of Secured Debt and Announces Management Changes
October 03, 2019 07:30 ET
|
VIVUS, Inc.
-Reduction of $48.6 million of Secured Debt will result in total interest savings of $10.5 million--Organizational change streamlines commercial operations- CAMPBELL, Calif., Oct. 03, 2019 ...
VIVUS to Present at Upcoming Conferences
August 28, 2019 07:30 ET
|
VIVUS, Inc.
CAMPBELL, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today announced that John Amos, Chief Executive Officer at VIVUS, will...
VIVUS to Share Qsymia® Safety and Efficacy Data with a Global Audience at ICOMES & AOCO 2019
August 27, 2019 07:30 ET
|
VIVUS, Inc.
-Conference in Seoul provides opportunity to introduce an international audience to the clinical safety and benefits of Qsymia following its approval in the Republic of Korea- CAMPBELL, Calif., Aug. ...
New Pilot Clinical Study Results Demonstrate that Addition of VIVUS’ Qsymia® to Gastric Sleeve Surgery Significantly Improves Weight Loss Compared with Surgery Alone
August 20, 2019 07:30 ET
|
VIVUS, Inc.
-Data published in Surgery for Obesity and Related Diseases also show that patients in the Qsymia group lost more than twice as much weight during preoperative treatment compared with control group- ...
VIVUS Reports Second Quarter 2019 Financial Results
August 06, 2019 16:05 ET
|
VIVUS, Inc.
CAMPBELL, Calif., Aug. 06, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (NASDAQ: VVUS) (the “Company”), a specialty pharmaceutical company committed to the development and commercialization of innovative...
VIVUS Announces Approval of Qsymia® in the Republic of Korea
August 05, 2019 07:30 ET
|
VIVUS, Inc.
VIVUS receives $2.5 million milestone payment CAMPBELL, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) (the “Company”), a biopharmaceutical company, announced today that its...
VIVUS to Host Second Quarter Business Update and Financial Results Conference Call on Tuesday, August 6, 2019
July 23, 2019 07:30 ET
|
VIVUS, Inc.
CAMPBELL, Calif., July 23, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) today announced that it will report financial results and provide a business update for the second quarter of 2019...
VIVUS and Nordmark Amend Contract Manufacturing Agreement to Supply Current and Future Demand for PANCREAZE®
June 26, 2019 16:05 ET
|
VIVUS, Inc.
-Companies will also collaborate to develop additional PANCREAZE dose formulations and an advanced formulation with an extended shelf life- CAMPBELL, Calif., June 26, 2019 (GLOBE NEWSWIRE) -- ...